Skip to content
value.today
Codexis, Inc. logo

Codexis, Inc.

Codexis, Inc. is listed today as Codexis, Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Codexis, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2019$50 MPrivate placement after listing$50 to $250 million

Codexis, Inc.: Private sale, Jun 2019

Investors in this round

1 investor had bought by the notice of Jun 20, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Codexis, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gordon Sangster · Executive Officer
  • John Nicols · Executive Officer, Director
  • Bernard Kelley · Director
  • Byron Dorgan · Director
  • David Smith · Director
  • Dennis Wolf · Director
  • Kathleen Glaub · Director
  • Pam Cheng · Director
  • Patrick Yang · Director
  • Thomas Baruch · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gordon Sangster, Senior Vice President and Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 20, 2019. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Codexis, Inc., its revenue in fiscal 2025 came from these product and service lines: Research and development revenue $44.36 million (63%).

    Annual report (SEC XBRL) · Dec 2025

  • Codexis, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2019).

    SEC Form D · Jun 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2019

Products and services#

No products or services of Codexis, Inc. are on record.

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in Codexis, Inc.
InvestorKindAmountRoundRoleSource
Biomedical Sciences Investment Fund Pte Ltd.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2010)SEC Form 3
CMEA Ventures Life Sciences 2000, Civil Law PartnershipVenture capitalnot statednot statedHeld Series B, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Cmea Ventures Life Sciences 2000 LPVenture capitalnot statednot statedHeld Series B, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
CMEA Ventures LS Management 2000, L.P.Venture capitalnot statednot statedHeld Series B, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
EDB Investments Pte Ltd.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Equilon Enterprises LLCOthernot statednot statedHeld Series D, E and F preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Maxygen IncCompanynot statednot statedHeld Series A, B and D preferred stock, 10% owner, director (Form 3, 2010)SEC Form 3
Royal Dutch Shell PLCCompanynot statednot statedHeld Series D, E and F preferred stock, 10% owner (Form 3, 2010)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Codexis, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Codexis, Inc.
NameRoleNamed in
Gordon SangsterExecutive officerJun 2019
John NicolsExecutive officerJun 2019
Bernard KelleyDirectorJun 2019
Byron DorganDirectorJun 2019
David SmithDirectorJun 2019
Dennis WolfDirectorJun 2019
John NicolsDirectorJun 2019
Kathleen GlaubDirectorJun 2019
Pam ChengDirectorJun 2019
Patrick YangDirectorJun 2019
Thomas BaruchDirectorJun 2019

About

American protein engineering company.

Went public since 2010. Its SEC number is that of a company listed on a stock exchange.